The Use of Immunotherapy To Treat T-cell Acute Lymphocytic Leukemia

Abstract

This review discusses the potential impact immunotherapy has for the advancement of T-ALL treatments, specifically the use of monoclonal antibodies and chimeric antigen receptors for treating patients diagnosed with the cancer. However, significant obstacles remain that challenge the effectiveness of these treatments, particulary the shared expression of antigens among healthy and leukemic T cells. Designing immunotherapies that have the ability to specifically target malignant T cells, as well as protecting healthy T cells from destruction, is crucial to developing a successful treatment. In additon to exploring the possible immunotherapies used to treat T-ALL, we will cover two ongoing clincial trials the hope to test the effectiveness of certain immunotherapies in patients with T-ALL. There is still much to learn about the complexities of immunotherapy, and although it is still in its early stages of development, immunotherapy has shown promise in improving outcomes for T-ALL patients.